The function of the pleckstrin homology domain in BCR-ABL-mediated leukemogenesis The BCR-ABL tyrosine kinase is central to the pathogenesis of chronic myeloid leukemia (CML) and Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL). Depending on the breakpoint in BCR, several BCR-ABL variants can be generated (Figure 1a ), such as p190 BCR-ABL and p210 BCR-ABL , which are detected in the majority of cases of Ph-positive ALL and CML, respectively. 1 The p190 BCR-ABL isoform was previously reported to show elevated tyrosine kinase activity, 2, 3 although the structural basis for increased kinase activity has not Letters to the Editor been established and kinase activity alone fails to explain the predilection of p190 BCR-ABL for transformation of lymphoid cells. At the sequence level, the genetic information retained in p210 BCR-ABL but not in p190 BCR-ABL encodes the diffuse poorly differentiated B-cell lymphoma (DBL)-like and pleckstrin homology (PH) domains of BCR. Although earlier studies have suggested a positive role for the DBL-like domain in p210 BCRÀABL -induced transformation, 4 the function of the PH domain in leukemogenesis has not been studied in isolation. In this study, we used a rare, naturally occurring variant of BCR-ABL (p200 BCR-ABL ; Figure 1a ) that retains the DBL-like, but not the PH domain to analyze the role of the PH domain in BCR-ABL-induced leukemia.
We introduced three BCR-ABL variants (p190 BCR-ABL , p200
BCR-ABL and p210 BCR-ABL ) into 32D cells and found that all three BCR-ABL proteins transformed the cells to growth factor independence (data not shown). Immunoblot analysis of bulk cultures expressing comparable levels of p190 BCR-ABL , p200
BCR-ABL or p210 BCR-ABL (Figure 1b) showed similar global levels of cellular phosphotyrosine, as detected using an antiphosphotyrosine antibody (Figure 1c Figure 1 ). These rather subtle differences are in contrast with an earlier study that showed a substantial increase in autophosphorylation and substrate phosphorylation in recombinant p190
BCR-ABL protein compared with p210 BCR-ABL . 3 However, our data are comparable to those reported by Li et al.,
2 who observed a 1.5-fold increase in p190 BCR-ABL kinase activity compared with p210 BCR-ABL in a similar experimental system. These slight differences in kinase activity between the three BCR-ABL variants are consistent with the lack of changes in global phosphotyrosine levels, which are apparent on immunoblots of total cellular extracts. In light of earlier reports that have suggested differences in STAT6 phosphorylation in Ba/F3 cells expressing p190 BCR-ABL or p210 BCR-ABL , 5, 6 we performed immunoblot experiments to determine whether this difference was upheld in p200 BCR-ABL . We found STAT6 phosphorylation to be much higher in BaF/3 cells expressing p190 BCR-ABL or p200 BCR-ABL in comparison with those expressing p210 BCR-ABL (Figure 1d ), indicating that deletion of the PH domain is sufficient to lead to STAT6 activation in a lymphoid cell setting. An initial comparison of the three BCR-ABL variants in murine bone marrow colony formation assays indicated that the p190 BCR-ABL and p200 BCR-ABL variants are only slightly more transforming than p210 BCR-ABL in myeloid colony assays (Supplementary Figure 2a) and substantially more transforming in B-cell colony assays (Supplementary Figure 2b) . To explore the role of the PH domain of BCR-ABL in vivo, we first compared p190 BCR-ABL , p200 BCR-ABL and p210 BCRÀABL in a well-established mouse model system in which transplantation of bone marrow from 5-FU-treated mice infected with BCR-ABL retrovirus into lethally irradiated recipients leads to a myeloproliferative disease resembling CML (Figure 1e ). All mice transplanted with BCR-ABL-infected marrow (N ¼ 6 per group) developed a myeloproliferative syndrome, as evidenced by fluorescence-activated cell sorting analysis of blood, bone marrow, spleen and liver tissues (Figure 1g ). Mice transplanted with p190 BCR-ABL -or p200 BCR-ABL -infected marrow showed a median disease latency (the interval between transplantation and the first abnormal white blood cell count) of 12 days, whereas the median latency was 14 days for mice transplanted with p210
BCR-ABL -infected marrow (Po0.05). Median survival was also slightly shorter in recipients of p190 BCR-ABL -and p200 BCR-ABL -infected marrow (14 and 14.5 days, respectively) compared with recipients of p210 BCR-ABL -infected marrow (16 days, Po0.05). Together, these results suggest that BCR-ABL lacking the PH domain shows similar oncogenicity to that of p190 BCR-ABL , inducing a slightly more aggressive CML-like myeloproliferative disease in mice than the p210 BCR-ABL variant. In Ph-positive leukemia patients, p190
BCR-ABL is strongly associated with a B-cell ALL (B-ALL) disease phenotype, whereas BCR-ABL were alive on day 120 after transplant, apart from one animal that died from a non-leukemia-related cause.
The relationship between different forms of the BCR-ABL tyrosine kinase and clinical disease phenotype has attracted considerable attention. The general notion is that greater BCR sequence conservation in the fusion protein results in a less aggressive disease. 7 This is largely based on the strong association between p190 BCR-ABL and Ph-positive ALL, which carries a poor prognosis compared with the predominantly p210 BCR-ABL -driven CML. Differences between these BCR-ABL variants could be related to the cell-type-specific transforming capacity of p190 BCR-ABL versus p210 BCR-ABL , or to an innate propensity of certain cell types for specific BCR rearrangements. It has also been suspected that preservation of the guanine nucleotide exchange factor (GEF) activity toward small Rho GTPases by the DBL-like domain, which is absent in the p190 BCR-ABL variant, may attenuate the disease phenotype. However, replacement of the DBL-like domain with irrelevant, non-homologous sequences strongly compromises the transforming capacity of p210 BCR-ABL , consistent with a positive regulatory role in this BCR-ABL variant. 4 In addition, the invariant organization of the DBL and PH domains in RhoGEFs suggests an important role of PH for DBL function. Suggested mechanisms include allosteric regulation of GEF activity through phosphoinositide binding 8, 9 and direct interaction with the substrate GTPase. 10 Our data suggest that the PH domain may also contribute to the transformational capacity of BCR-ABL variants and that there may be functional interplay between these two domains because deletion of the PH domain alone (p200 BCR-ABL ) phenocopies deletion of both domains (p190 BCRÀABL ). In general, PH domains are best characterized as lipid-binding domains that tether proteins to phosphoinositide components of the cell membrane. The subtle increase we observed in kinase activity for BCR-ABL variants lacking the PH domain may account for their slightly increased overall transformation potency, evident as mildly enhanced myeloid colony formation and shortened latency and survival in the murine CML model. However, these minor differences are unlikely to explain how absence of the PH domain affects the ability to induce B-ALL in mice transplanted with non-5-FU-treated marrow, suggesting a more complex mechanism may be operational in this setting. Thus, PH domain-dependent signals emanating from p210 BCR-ABL , such as a pathway inhibiting STAT6 phosphorylation, may suppress the transformation of B lymphoblasts while still retaining the capacity to transform myeloid cells. Although the deletion of the PH domain alone is sufficient to increase the transformation potency of BCR-ABL toward B cells in the murine B-ALL model, a slight further increase is observed with the additional deletion of BCR exons 2-8. This is consistent with the data presented by Li et al., which showed that p190 BCR-ABL but not p210 
